This info is related to Lux in B-cell malignancies. It is why I posted it here. Pirto is also in several combination trials with most likely some impressive results to come. I don't know whether you know it or not, but Merck runs a combo trial of Nemtabrutinib, aka ARQ-531, with Zilovertamab Vedotin, an ADC made by ONCT guys. They have several cohorts including MCL.
News 
Market Data 
Discover 
AI
